Abstract
Background Copy number variants platforms, as critical supports for genetic diagnosis, have been well implemented in prenatal diagnosis. However, numerous severe conditions with underlying single-gene defects are not included in current invasive prenatal screening. To bridge this gap, an expanded chromosomal microarray analysis was developed, employing a meticulous designed single nucleotide polymorphism chip. This chip incorporated additional probes to augment its efficacy in screening for spinal muscular atrophy and diagnosing monogenic disorders.
Objective(s) This study aimed to evaluate the accuracy, efficacy, and incremental yield of expanded chromosomal microarray, compared with karyotype analysis and low-depth genome sequencing for routine prenatal diagnosis.
Study Design In this prospective study, total of 512 fetuses were included in this study. In this study three distinct diagnostic techniques-karyotype analysis, low-depth genome sequencing, and expanded chromosomal microarray-were processed to evaluate each sample. Aneuploidies and multigene copy number variations were detected and analyzed in a blinded fashion. SMN1 exonic copy number variations were confirmed by multiplex ligation-dependent probe amplification and single nucleotide variations were confirmed by sanger sequencing.
Results Overall, expanded chromosomal microarray identified genetic abnormalities in 91 out of 512 cases (17.6%). The encountered rate was significantly higher than the rates observed with low-depth genome sequencing (66 out of 512 cases, 12.9%) and conventional chromosome karyotyping (42 out of 512 cases, 8.2%). Expanded chromosomal microarray not only detected all these non-mosaic aneuploidies and copy number variations in 62(12.1%) diagnosed cases identified by low-depth genome sequencing (low-depth genome sequencing), but also detected 9 cases with regions of homozygosity, 10(2.0%) cases with exonic deletions (SMN1 and DMD), and 13(2.5%) cases with single nucleotide variations.
Conclusions Compared with low-depth GS, expanded chromosomal microarray increased the additional detection rate by 4.7% (24/512). Compared with traditional chromosomal microarray, expanded chromosomal microarray increased the additional detection rate by 3.9% (20/512) in 512 fetuses. Although the expanded chromosomal microarray (ECMA) has limited accuracy for detecting single nucleotide variations, its screening capacity is significantly enhanced when complemented with Sanger sequencing validation. Using expanded chromosomal microarray, we detected not only copy number variations, but also exonic deletions, regions of homozygosity with high accuracy in an acceptable turnaround time (2-3 weeks). Our results suggest that expanded chromosomal microarray has the potential to be a promising prenatal diagnostic tool with incremental yield of screening exonic copy number variations in SMN1.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Key R&D Program of China under grant numbers 2023YFC2705600, 2023YFC2705601, 2023YFC2705603, 2021YFC2701002 to C.X. and 2022YFC2703702 to S.C.; the National Natural Science Foundation of China under grant numbers 81971344 and 82171677 to C.X., 82192864 to S.C. and 82301935 to X.L.; the Shanghai Municipal Commission of Science and Technology Program under grant numbers 22S31901500 and 21Y21901002 to C.X.; the Natural Science Foundation of Shanghai under grant number 23ZR1408000 to S.C.; the Shanghai Municipal Commission of Health and family planning under grant number 202140110 to S.C.; the Shanghai Frontiers Science Research Center of Reproduction and Development foundation to H.H.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Committee of the Obstetrics & Gynecology Hospital of Fudan University gave ethical approval for this work(2022-46).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts of interests: The authors declare that they have no conflict of interest.
Source of Funding: This work was supported by the National Key R&D Program of China under grant numbers 2023YFC2705600, 2023YFC2705601, 2023YFC2705603, 2021YFC2701002 to C.X. and 2022YFC2703702 to S.C.; the National Natural Science Foundation of China under grant numbers 81971344 and 82171677 to C.X., 82192864 to S.C. and 82301935 to X.L.; the Shanghai Municipal Commission of Science and Technology Program under grant numbers 22S31901500 and 21Y21901002 to C.X.; the Natural Science Foundation of Shanghai under grant number 23ZR1408000 to S.C.; the Shanghai Municipal Commission of Health and family planning under grant number 202140110 to S.C.; the Shanghai Frontiers Science Research Center of Reproduction and Development foundation to H.H.
Date sharing: All the data generated or analyzed in this study are included in this published article.
Ethical approval: Ethical approval for this study was “Construction and Application Evaluation of a Prenatal Detection System Based on Novel Microarray Technology” obtained from ethical Committee of the Obstetrics & Gynecology Hospital of Fudan University (2022-46).
Patient consent: Informed consent was obtained from all the study participants at the time of providing samples.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos